Saxenda vs Wegovy: Old-Generation vs New-Generation GLP-1 for Weight Loss
Saxenda and Wegovy are both liraglutide-based and semaglutide-based GLP-1 drugs from Novo Nordisk, both injected under the skin for weight management. But they are separated by almost a decade of GLP-1 drug development — and the clinical data between the two is not close.
The molecules
Saxenda contains liraglutide at 3 mg. Liraglutide is a GLP-1 receptor agonist with a half-life of approximately 13 hours — which is why it requires daily injection. Saxenda was FDA-approved for obesity in December 2014.
Wegovy contains semaglutide at 2.4 mg. Semaglutide is a structural modification of liraglutide that binds more tightly to albumin in the blood, extending its half-life to approximately 168 hours (7 days). That longer half-life is why Wegovy can be injected once weekly. Wegovy was FDA-approved for obesity in June 2021.
Both are GLP-1 receptor agonists. Semaglutide's structural modifications also produce higher receptor affinity and longer central satiety signalling duration — contributing to greater weight loss at the equivalent metabolic exposure.
The head-to-head data
The STEP 8 trial (published NEJM 2022) directly compared semaglutide 2.4 mg versus liraglutide 3 mg in 338 adults with obesity over 68 weeks:
| Drug | Mean weight loss | Patients achieving ≥15% loss |
|---|---|---|
| Semaglutide 2.4 mg (Wegovy equivalent) | −15.8% | 70.9% |
| Liraglutide 3 mg (Saxenda equivalent) | −6.4% | 25.6% |
That is a more than 2:1 efficacy advantage for semaglutide. This is the benchmark comparison.
Outside the head-to-head:
- SCALE Obesity trial (Saxenda, 56 weeks): approximately 8% mean weight loss
- STEP 1 trial (Wegovy 2.4 mg, 68 weeks): approximately 14.9–17.4% mean weight loss
Dosing and injection frequency
| Saxenda | Wegovy | |
|---|---|---|
| Active ingredient | Liraglutide | Semaglutide |
| Dose | 3 mg | 2.4 mg |
| Injection frequency | Daily | Weekly |
| Titration | 0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg over 5 weeks | 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks |
| Storage | Refrigerated (before opening); room temp up to 30 days | Refrigerated; similar |
Once-weekly versus daily injection is meaningful for adherence. Saxenda requires 365 injections per year; Wegovy requires 52.
Why Saxenda is still prescribed
If Wegovy is clearly superior on efficacy and less burdensome on dosing, the question is why Saxenda remains in use.
Insurance coverage: Saxenda has been on commercial insurance formularies since 2014 — a full 7 years before Wegovy. For plans that have not yet added Wegovy for obesity, Saxenda may still be covered. A patient facing the choice between cash-pay Wegovy ($349/month via NovoCare) and an insured Saxenda with a lower copay may find Saxenda the more accessible option.
Tolerability: Some patients tolerate one GLP-1 molecule better than another. GI side effects vary by individual. If a patient has significant intolerance to semaglutide, liraglutide's different pharmacokinetic profile may produce a different side effect experience.
Clinical transition: Saxenda is sometimes used as a "bridge" while appealing for Wegovy coverage — the patient continues on a GLP-1 drug (and maintains some weight management benefit) while the PA and appeals process runs for Wegovy.
Side effects comparison
Both drugs produce GI side effects front-loaded at each dose step: nausea, vomiting, diarrhoea, constipation. The Saxenda trial GI rates are generally similar to Wegovy. One difference: because Saxenda is daily and reaches steady-state quickly, GI effects at a given dose may settle faster than the weekly-injection Wegovy, where plasma levels are still building over the first few weeks at each dose.
Both share the thyroid carcinoma black-box warning and pancreatitis risk cautions.
The current-generation perspective
For a patient starting GLP-1 therapy for obesity in 2026 with unrestricted access to either drug, Wegovy is the clear clinical first choice based on efficacy and dosing convenience. Saxenda's role is now primarily:
- The insurance-covered fallback when Wegovy is not yet on the formulary
- A transition drug during appeal/PA processes
- A second-line option for semaglutide-intolerant patients
For the most effective current GLP-1 for weight loss, including tirzepatide comparison, see best GLP-1 for weight loss 2026.
Frequently asked questions
Which is better, Saxenda or Wegovy?
Wegovy produces approximately twice the weight loss — 15–17% vs 8–9% for Saxenda. The STEP 8 head-to-head trial (68 weeks) showed 15.8% weight loss for semaglutide 2.4 mg versus 6.4% for liraglutide 3 mg (Saxenda's equivalent). Wegovy is also weekly rather than daily. By efficacy and convenience, Wegovy is clearly ahead.
Why would anyone choose Saxenda over Wegovy?
The main reason is insurance. Saxenda has been on formularies since 2014 and is covered by some plans that do not yet cover Wegovy for obesity. A patient whose insurance covers Saxenda but not Wegovy may start on Saxenda while appealing for Wegovy coverage, or simply because the covered option is better than a cash-pay option for them. Some patients also prefer daily dosing for adherence pattern reasons.
Is Saxenda still being prescribed in 2026?
Yes. Saxenda remains FDA-approved and on the market. It is prescribed when: (1) insurance covers it but not Wegovy; (2) a patient has tried and cannot tolerate semaglutide; (3) a prescriber has clinical reasons to prefer the shorter-acting liraglutide profile. It is less commonly initiated as a first-choice option now that semaglutide is widely available.
Does Saxenda have a cardiovascular benefit like Wegovy?
The LEADER trial (liraglutide, which is the same molecule as Saxenda at 1.8 mg — lower dose than Saxenda's 3 mg obesity dose) showed cardiovascular benefit in T2D patients. Saxenda (liraglutide 3 mg for obesity) does not have an FDA-approved cardiovascular risk-reduction indication in the same way Wegovy does (SELECT trial, 20% MACE risk reduction in patients with established CVD without diabetes).